Autopsy report · NCT05687617

Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

“Recruitment lower than expected and negative results.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Laval University

Sponsor type

University, hospital or other

Conditions

Gastric Cancer; Gastric Adenocarcinoma; Peritoneal Carcinomatosis; Peritoneal Metastases

Interventions

Indocyanine green

Participants

11

Sites

2

Countries

Canada

Trials that died the same way

• Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
  “Lower than anticipated recruitment” (89% match in meaning)
• NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
  “Low recruitment” (80% match in meaning)
• Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer
  “low recruitment rate” (79% match in meaning)
• NHFOV Versus NCPAP to Prevent Exubation Failure
  “Poor recruitment rate” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.